Awesome Update !!! *** On track to Achieve Target of having 25-30 hospitals with VMS+ by year end ***
Toronto, Ontario – TheNewswire – November 22 , 2021 - Ventripoint Diagnostics Ltd. (" Ventripoint " or the " Company "), (TSXV:VPT ) ; ( OTC:VPTDF) is pleased to announce that it has received four more orders for the VMS+3.0 whole-heart analysis systems. These units are being manufactured at the Ventripoint facility and are expected to be installed by the end of the calendar year.
“In spite of all the difficulties facing hospitals during the pandemic, the Company continues to receive orders for VMS+3.0 units, which speaks to growing demand for rapid effective cardiac diagnostics to clear the backlog of patients and address the growing numbers of patients with long-COVID,” stated Dr. George Adams, CEO of Ventripoint.
These four units will be installed in leading pediatric and adult cardiovascular centres in the UK, Canada and USA and add to the existing installed base of 21 VMS+ units in Canada, United Kingdom, Europe, USA and China. The Company targeted to deploy 25-30 units by the end of 2021 and is on track to achieve this goal.
Ventripoint expects to receive additional purchase orders by year end but will not be able to install these units until early 2022 as it takes a few weeks to schedule the installation and training in a busy echocardiography clinic.
The Company will announce the sites as they are installed and permission is obtained to name the hospitals who have adopted the VMS+ approach to improved cardiac diagnostics.
Each installation further validates VMS+ technology as the alternative to cardiac MRI imaging, offering cost effective solutions to ultrasound clinics everywhere - a massive market opportunity.
About Ventripoint Diagnostics Ltd.
Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.
For further information, please contact:
Dr. George Adams